cabozantinib,atezolizumab
roche
['contact-3']
if you want understand the implication of contact-3 data presented at #asco23- i point you to this excellent commentary from and 
GU Oncologist/Clinical Trials/ Experimental Therapeutics @UCD_Cancer @UCDavisHealth via @uofcincy @GoBEARCATS. Tweets= My opinions #RCC #ASCO #immunotherapy